Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MF59-adjuvanted H5N8 vaccine immunogenicity in H5N1-primed vs naive adults
2025-522593-36-00Phase 4Authorised
- Sponsor
- Helse Bergen
- Start
- Sep 2025
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4 trial of H5N8 zoonotic influenza vaccine in Avian influenza A virus subtype H5N8 infection (H5N8) and influenza (2 arms), sponsored by Helse Bergen. Planned start Sep 2025; status: authorised.
02
Drugs
H5N8 zoonotic influenza vaccine
03
Conditions
Avian influenza A virus subtype H5N8 infection (H5N8)influenza
Beyond the preview
Go deeper on 2025-522593-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522593-36-00.